NCT04703153|Unknown
LIQUIK: LIQUId Biopsy for Detection of Actionable Genomic BiomarKers in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
LIQUIK
Loading search results
LIQUIK
Sponsor study identifier
observational
151
1 country
5
Study Start
April 5, 2021
Actual (reported)Primary Completion
December 31, 2022
Actual (reported)Study Completion
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
To explore the non-inferiority of a cfDNA amplicon-based liquid biopsy technology vs. standard of care tissue biopsy-based NGS in detecting guideline- recommended biomarkers in patients with metastatic non-squamous Non-small Cell Lung Cancer (NSCLC), amongst other endpoints. To explore the non-inferiority of cfDNA-based LiquidHALLMARK test vs. cfDNA-based liquid biopsy competitor, both qualitatively and quantitatively for actionable mutation (percentage of allele frequency) profile results in a population of subjects who have at least one actionable mutation detected by tissue biopsy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 7, 2021
Actual (reported)January 11, 2021
Actual (reported)April 5, 2021
Actual (reported)December 31, 2022
Actual (reported)December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Demonstrate the non-inferiority of cfDNA-based LiquidHALLMARK liquid biopsy assay vs. SOC tissue biopsy based NGS assay for mutation profile results
Explore the non-inferiority of cfDNA-based LiquidHALLMARK liquid biopsy assay vs. SOC tissue biopsy based NGS assay for mutation profile results in a population of subjects who have at least one of nine actionable genes (G9) - EGFR, ALK, RET, ROS1, NTRK fusions, MET, BRAF, ERBB2 and KRAS- detected by tissue biopsy.
34 months
Treatment-naïve newly diagnosed, histologically confirmed, metastatic NSCLC patients
California Research Institute
Los Angeles, California, 90027, United States
University of Miami, Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Kaiser Permanente Hawaii Region Center for Integrated Health Care Research
Honolulu, Hawaii, 96817, United States
University of Maryland - Marlene and Stewart Greenbaum Cancer Center
Baltimore, Maryland, 21201, United States
New Jersey Cancer Care
Belleville, New Jersey, 07109, United States
Samol J, Ng D, Poh J, Tan MH, Dawar R, Carney J, Orsini J Jr, Scilla K, Tan YO, Chin TM, Toh CK, Goh BC, Lopes G. Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non-Small Cell Lung Cancer (LIQUIK). JCO Precis Oncol. 2025 Jun;9:e2500181. doi: 10.1200/PO-25-00181. Epub 2025 Jun 26.
151 participants (actual enrollment reported by the registry).
First Submitted
January 7, 2021
First Posted
January 11, 2021
Study Start
April 5, 2021
Actual (reported)A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer
Contact the study team to confirm eligibility.
Primary Completion
December 31, 2022
Actual (reported)Study Completion
December 31, 2024
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 9, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: